Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 7:00AM
Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused
on therapeutics for acute care settings, today announced that Gerri
Henwood, President and Chief Executive Officer, will give a
corporate presentation at the H.C. Wainwright Global Life Sciences
Conference, being held virtually March 9-10, 2021.
The presentation will be made available for
on-demand listening beginning Tuesday, March 9th at 7:00 a.m.
Eastern Time and may be accessed on the “Presentations” page within
the investors section of the Baudax Bio website at
https://www.baudaxbio.com/news-and-investors. The recording will be
made available for a period of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on therapeutics for acute care settings. The launch of Baudax Bio’s
first commercial product ANJESO® began in June 2020 following its
approval by the U.S. Food and Drug Administration in February 2020.
ANJESO is a once daily IV NSAID with preferential Cox-2 activity,
which has successfully completed three Phase III clinical trials,
including two pivotal efficacy trials, a large double-blind Phase
III safety trial and other studies for the management of moderate
to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of
other pharmaceutical assets including two novel neuromuscular
blocking agents (NMBAs) and a proprietary chemical reversal agent
specific to these NMBAs which is currently in preclinical studies,
and intranasal dexmedetomidine which is being developed for
possible uses in pain or sedation. For more information please
visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:Argot PartnersSam
Martin / Claudia Styslinger(212)
600-1902baudaxbio@argotpartners.com
Baudax Bio, Inc.Ryan D. Lake(484)
395-2436rlake@baudaxbio.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024